Use of disease-modifying drugs (tocilizumab, tofacitinib, and baricitinib—a biological or synthetic target specific) in patients hospitalized with COVID-19
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Digital revista |
| Language: | English |
| Published: |
Associação Médica Brasileira
2022
|
| Online Access: | http://old.scielo.br/scielo.php?script=sci_arttext&pid=S0104-42302022000100003 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|